Not sure if I have missed it, but in the quarterly announcement the following was stated
”For our cardiovascular product Revascor®, we had a very productive meeting with the FDA this month which included discussion of a unifying mechanism of action across the continuum of heart failure with inflammation in adults, and potential approval pathways in these patients. The FDA will provide written minutes from the meeting in March.
Should we expect an announcement from MSB or have these already been published somewhere already?
Not sure if I have missed it, but in the quarterly announcement...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.075(6.91%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $18.64M | 15.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 158917 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 23809 | 6 |
View Market Depth
| Last trade - 15.43pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.075 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3730649 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |